Study Shows Tirzepatide Improves Heart Failure Outcomes and Quality of Life in Obese Patients
November 22, 20243m 38s
Audio is streamed directly from the publisher (play.hubhopper.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the composite risk of cardiovascular death or worsening heart failure and improved health status compared to placebo, though it was associated with higher gastrointestinal side effects.
For summary, click here.
Packer M, Zile MR, Kramer CM, et al. (2024). “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.” New England Journal of Medicine. DOI: 10.1056/NEJMoa2410027